Articles by Jill Wechsler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jill Wechsler

Experts Ponder Ways to Fill Pharma Pipeline

FDA, NIH and industry seek new strategies to spur drug development and promote access to therapies.
May 2, 2011

FDA, NIH and industry seek new strategies to spur drug development and promote access to therapies.

Health-Reform Controversies

Courts and Congress seek to reshape policies and programs.
Apr 2, 2011

Courts and Congress seek to reshape policies and programs.

Drug Safety and Shortages Challenge Manufacturers

As drug shortages make headlines, FDA tests the Sentinel safety system and its efect on healthcare.
Mar 2, 2011

As drug shortages make headlines, FDA tests the Sentinel safety system and its efect on healthcare.

FDA Faces Internal Changes and Challenges

Food-safety, transparency, and counterfeit-drug growth will tax agency resources.
Feb 2, 2011

Food-safety, transparency, and counterfeit-drug growth will tax agency resources.

Cost and Compliance Dominate Agenda for 2011

Top priorities for manufacturers include user fees, new health initiatives, and regulatory compliance.
Jan 2, 2011

Top priorities for manufacturers include user fees, new health initiatives, and regulatory compliance.

Pharma Faces New Political Landscape

Republican gains in Congress create uncertainty for healthcare reform, drug regulation, and biomedical research.
Dec 2, 2010

Republican gains in Congress create uncertainty for healthcare reform, drug regulation, and biomedical research.

Comparative Research Poses Challenges

A new center may provide evidence for improving care, but could discourage coverage of treatments.
Nov 2, 2010

A new center may provide evidence for improving care, but could discourage coverage of treatments.

Administration Seeks to Modernize Vaccine Production

President Obama and HHS eye innovation and countermeasures to protect public health.
Oct 2, 2010

President Obama and HHS eye innovation and countermeasures to protect public health.

FDA Struggles with Risk Management and Drug Safety

Weighing the pros and cons of REMS for bringing risky products to market.
Sep 2, 2010

Weighing the pros and cons of REMS for bringing risky products to market.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here